Cbl is a multi-adaptor protein involved in ligand-induced downregulation of receptor tyrosine kinases. It is thought that Cbl-mediated ubiquitination of active receptors is essential for receptor degradation and cessation of receptor-induced signal transduction. Here we demonstrate that Cbl additionally regulates epidermal growth factor (EGF) receptor endocytosis. Cbl rapidly recruits CIN85 (Cbl-interacting protein of 85K; ref. 6) and endophilins (regulatory components of clathrin-coated vesicles) to form a complex with activated EGF receptors, thus controlling receptor internalization. CIN85 was constitutively associated with endophilins, whereas CIN85 binding to the distal carboxy terminus of Cbl was increased on EGF stimulation. Inhibition of these interactions was sufficient to block EGF receptor internalization, delay receptor degradation and enhance EGF-induced gene transcription, without perturbing Cbl-directed receptor ubiquitination. Thus, the evolutionary divergent C terminus of Cbl uses a mechanism that is functionally separable from the ubiquitin ligase activity of Cbl to mediate ligand-dependent downregulation of receptor tyrosine kinases.

CIN85 is a multidomain adaptor protein implicated inCbl-mediated down-regulation of receptor tyrosine kinases. CIN85 binding to Cbl is increased after growth factor stimulation and is critical for targeting receptor tyrosine kinases to clathrin-mediated endocytosis. Here we report the identification of a novel polyproline-arginine motif (PXXXPR), specifically recognized by the SH3 domains of CIN85 and its homologue CMS/CD2AP. This motif was indispensable for CIN85 binding to Cbl/Cbl-b, to other CIN85 SH3 domains' effectors, and for mediating an intramolecular interaction between the SH3-A domain and the proline-rich region of CIN85. Individual SH3 domains of CIN85 bound to PXXXPR peptides of Cbl/Cbl-b with micromolar affinities, whereas an extended structure of two or three SH3 domains bound with higher stoichiometry and increased affinity to the same peptides. This enabled full size CIN85 to simultaneously interact with multiple Cbl molecules, promoting their clustering in mammalian cells. The ability of CIN85 to cluster Cbl was important for ligand-induced stabilization of CIN85⅐Cbl⅐epidermal growth factor receptor complexes, as well as for epidermal growth factor receptor degradation in the lysosome. Thus, specific interactions of CIN85 SH3 domains with the PXXXPR motif in Cbl play multiple roles in down-regulation of receptor tyrosine kinases.Growth factor binding to receptor tyrosine kinases (RTKs) 1 promotes receptor autophosphorylation, association of intracellular signaling proteins with receptors, and phosphorylation of multiple substrates (1). Subsequent changes in receptor substrates, including modulations of enzymatic activities and modifications of proteins and lipids, lead to the assembly of signaling networks that ultimately control cellular responses including cell proliferation, migration, or differentiation (2). Activated RTKs are also rapidly relocalized from the cell surface into the endosomal compartment, from where they can be recycled back to the plasma membrane or alternatively sorted to the lysosome for degradation. The processes of receptor internalization and endocytosis are regulated via a network of protein-protein and protein-lipid interactions, as well as protein post-translational modifications, such as phosphorylation or ubiquitination (3, 4). Several RTKs, including epidermal growth factor (EGF) receptors, are ubiquitinated and downregulated upon interactions with the Cbl family of ubiquitin ligases (5, 6). Cbl binding to EGF receptors occurs at the plasma membrane (7,8), and following receptor internalization they remain associated throughout the endocytic compartment (8, 9). Recent data (10) have indicated that attachment of a single ubiquitin, rather than polyubiquitin chains, to EGF and platelet-derived growth factor receptors is sufficient for receptor endocytosis and that multiple monoubiquitination events ensure proper receptor sorting and subsequent degradation in the lysosome.Cbl can also promote receptor endocytosis via a pathway that is functionally separable from its...

No abstract

CIN85 is a multidomain adaptor protein involved in Cbl-mediated down-regulation of epidermal growth factor (EGF) receptors. CIN85 src homology 3 domains specifically bind to a proline-arginine (PxxxPR) motif in Cbl, and this association seems to be important for EGF receptor endocytosis. Here, we report identification of novel CIN85 effectors, all containing one or more PxxxPR motifs, that are indispensable for their mutual interactions. These effectors include phosphatidyl-inositol phosphatases SHIP-1 and synaptojanin 2B1, Arf GTPase-activating proteins ASAP1 and ARAP3, adaptor proteins Hip1R and STAP1, and a Rho exchange factor, p115Rho GEF. Acting as a molecular scaffold, CIN85 clusters its effectors and recruits them to high-molecular-weight complexes in cytosolic extracts of cells. Further characterization of CIN85 binding to ASAP1 revealed that formation of the complex is independent on cell stimulation. Overexpression of ASAP1 increased EGF receptor recycling, whereas ASAP1 containing mutated PxxxPR motif failed to promote this event. We propose that CIN85 functions as a scaffold molecule that binds to numerous endocytic accessory proteins, thus controlling distinct steps in trafficking of EGF receptors along the endocytic and recycling pathways.

No abstract

We have previously described an inverse relationship between Cdx1 and Cdx2 mRNA levels and the extent of dysplasia and severity of clinical outcome in colorectal carcinoma, suggesting that altered expression of these genes was associated with colorectal carcinogenesis or tumor progression. To investigate further their involvement in the physiopathology of colorectal cancer, HT29 colon carcinoma cells that show very low Cdx expression were transfected with Cdx1 and/or Cdx2 cDNA to elicit their overexpression. Growth rate, tumorigenicity, resistance to apoptosis, and migration potential of the corresponding cells were analyzed. Growth rate of cells overexpressing Cdx2 decreased by half, whereas overexpression of Cdx1 had no effect. However, cells overexpressing both Cdxs had a growth rate reduced to 20% of control. In cells overexpressing Cdx1 or Cdx2, tumorigenicity and resistance to apoptosis induced by serum starvation, ceramide, or staurosporine were not changed compared with control cells; yet phorbol esterstimulated cell migration was decreased by 50%. In cells overexpressing both Cdx1 and Cdx2, tumorigenicity was decreased by 50%, resistance to apoptosis was significantly lowered, and stimulated cell migration was further decreased to 15% of control compared with cells expressing Cdx1 or Cdx2. Finally, cells overexpressing both Cdxs showed strongly decreased Bcl-2 expression, which could account for their increased sensitivity to apoptosis. These findings show that, in HT29 cells, both Cdx1 and Cdx2 genes must be expressed to reduce tumorigenic potential, to increase sensitivity to apoptosis, and to reduce cell migration, suggesting that the two genes control the normal phenotype by independent pathways. This may explain why loss of Cdx1 or Cdx2 expression is associated with tumor development and invasiveness in colorectal tumors.In an effort to characterize the mechanisms involved in colorectal cancer initiation and progression, we have developed a strategy based on the constitution of a large repertoire of transcripts from a colorectal tumor, all characterized by partial sequencing (1). Expression of these expressed sequence tags in normal and cancerous colon was compared, and those most differentially expressed were selected. Genes detected by these means may be causative or instrumental in tumor induction or/and progression. Looking for such genes, we found that the Cdx1 and Cdx2 homeotic genes were concomitantly down-regulated in about 85% of colorectal cancers (2). Such low expression of Cdx1 or Cdx2 in colon carcinoma was verified by immunohistochemistry (3, 4) and by reverse transcription polymerase chain reaction (5) studies. Cdx1 and Cdx2 are interesting candidates that could play a role in colon cancer pathology because Chawengsaksophak et al. (6) recently reported the occurrence of multiple intestinal adenomatous polyps in the proximal colon of Cdx2 ϩ/Ϫ mice, suggesting that lowering Cdx2 levels in intestinal cells would suffice to induce intestinal tumors. Also, Suh and Traber showed that expre...

No abstract

No abstract